Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Bayer Pakistan Private Limited

Private healthcare and pharmaceutical company - Bayer group · Karachi · Pakistan

Pakistan operating company of Bayer, active in healthcare and pharmaceutical products within the global Bayer group.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date23 Jul 2026Newest effective date among published current price records
Corporate profile evidence3 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Bayer Pakistan (Private) Limited
Company type
Private healthcare and pharmaceutical company - Bayer group
Address
Plot 23, Sector 22, Korangi Industrial Area, Karachi 74900, Pakistan · 74900
Phone
+92 21 35108000
Corporate source details checked
16 Aug 2026
Corporate profile completeness
75%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000003 Bayer Pakistan (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DSL 0611 24 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx24public portfolio records represented
REG16unique registrations represented
IDX24indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR20current validated price records
G7generic molecules in indexed catalogue
DF8dosage-form groups
TA5therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage83%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage96%
priced packs safely normalized per unit
Comparable-market coverage83%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixBayer Pakistan Private LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/bayer-pakistan-private-limitedGenerated 23 Sep 2026Anti-infectives9 · 38%Hematology & thrombosis8 · 33%Diagnostic agents3 · 13%Reproductive & genitourinary3 · 13%Cardiovascular1 · 4%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioBayer Pakistan Private LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/bayer-pakistan-private-limitedGenerated 23 Sep 202624presentationsTablet13 · 54%Cream3 · 13%Pessary2 · 8%Solution2 · 8%Implant1 · 4%Infusion1 · 4%Other forms2 · 8%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionBayer Pakistan Private LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/bayer-pakistan-private-limitedGenerated 23 Sep 202620comparable productsBelow peer median3 · 15%Near peer median0 · 0%Above peer median17 · 85%Company median price position+20.3%Lowest-price equivalents3Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsBayer Pakistan Private LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/bayer-pakistan-private-limitedGenerated 23 Sep 2026Zafa Pharmaceutical Laboratories (P…5 shared71% overlapSaffron Pharmaceuticals4 shared57% overlapMass Pharma (Pvt) Ltd.4 shared57% overlapAspin Pharma4 shared57% overlapNabiqasim Industries (Pvt) Ltd.,3 shared43% overlapM/s. Genix Pharma (Pvt) Ltd.3 shared43% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives9 products · 38%
Hematology & thrombosis8 products · 33%
Diagnostic agents3 products · 13%
Reproductive & genitourinary3 products · 13%
Cardiovascular1 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Anticoagulants8 products · 33%
Antifungals7 products · 29%
Radiographic contrast media3 products · 13%
Sex hormones / contraceptives3 products · 13%
Fluoroquinolone antibacterials2 products · 8%
Calcium-channel blockers1 products · 4%
Formulation footprint

Dosage forms

Tablet13 products
Cream3 products
Pessary2 products
Solution2 products
Implant1 products
Infusion1 products
Injection1 products
Other1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 XareltoRivaroxaban 8presentations 10 mg, 15 mg, 2.5 mg, 20 mg · Tablet #2 Canesten 1Clotrimazole 3presentations 0.5 g, 500 mg, 500 mg/5 g (10% w/w) · Tablet, Pessary, Cream #3 AveloxMoxifloxacin 2presentations 400 mg, 400 mg/250 mL · Tablet, Infusion #4 CanestenClotrimazole 2presentations 1% w/w (10 mg/g) · Cream #5 Canesten 6Clotrimazole 2presentations 0.1 g, 100 mg · Tablet, Pessary #6 Adalat LANifedipine 1presentations 30 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median315% of comparable products
Near market median0within ±5% of median
Above market median1785% of comparable products
Lowest-price equivalents3ties included
Company median price position +20.3% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Microgynon ED Fe 0.03 mg + 0.15 mgEthinylestradiol + Levonorgestrel · Tablet · 3 x 28's PKR 1.39/tablet-27.4% vs market median Xarelto 2.5 mgRivaroxaban · Tablet · 1 x 28's PKR 226.80/tablet+14.5% vs market median Xarelto 20 mgRivaroxaban · Tablet · 1 x 14's PKR 1,050.07/tablet+17.6% vs market median Xarelto 15 mgRivaroxaban · Tablet · 1 x 14's PKR 829.59/tablet+17.7% vs market median Avelox 400 mg/250 mLMoxifloxacin · IV infusion · 1 x 250ml PKR 9.14/mL+18.8% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 5shared generics Saffron Pharmaceuticals149 products · 50 generics 4shared generics Mass Pharma (Pvt) Ltd.120 products · 59 generics 4shared generics Aspin Pharma105 products · 44 generics 4shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 3shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 3shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers16Distinct registrations among indexed, published, presentation-validated products only
Verified price observations24
Products with a verified price24
Products with multiple price observations0
Source records with multiple versions22
Latest portfolio source check22 Sep 2026
Latest effective price date23 Jul 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

16 unique registration(s) · 24 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Adalat LA Nifedipine 30 mg Tablet 2 x 10's 044279 PKR 964.88 PKR 48.24/tablet 248% above median
Avelox Moxifloxacin 400 mg Tablet 1 x 5's 024653 PKR 1,490.83 PKR 298.17/tablet 62% above median
Avelox Moxifloxacin 400 mg/250 mL IV infusion 1 x 250ml 109733 PKR 2,285.19 PKR 9.14/mL 19% above median
Canesten Clotrimazole 1% w/w (10 mg/g) Cream 1 x 20g 107227 PKR 195.08 PKR 9.75/g 8% below median
Canesten Clotrimazole 1% w/w (10 mg/g) Cream 1 x 10g 107227 PKR 106.12 PKR 10.61/g 9% above median
Canesten 1 Clotrimazole 500 mg Vaginal tablet 1 x 1's 107224 PKR 188.80 PKR 188.80/tablet 48% above median
Canesten 1 Clotrimazole 0.5 g Tablet 1 x 1's 107224 PKR 188.80 PKR 188.80/tablet 24% above median
Canesten 1 Clotrimazole 500 mg/5 g (10% w/w) Vaginal cream 1 x 5g 107229 PKR 164.38 PKR 32.88/g No comparator
Canesten 6 Clotrimazole 100 mg Vaginal tablet 1 x 6's 107225 PKR 216.24 PKR 36.04/tablet 89% above median
Canesten 6 Clotrimazole 0.1 g Tablet 1 x 6's 107225 PKR 216.24 PKR 36.04/tablet 24% above median
Gastrografin Meglumine amidotrizoate + Sodium amidotrizoate 0.66 g/mL + 0.1 g/mL Contrast solution 1 x 100ml 000700 PKR 1,877.55 PKR 18.78/mL 27% below median
Jadelle Levonorgestrel 75 mg/implant (2 implants) Subdermal implant 1 Pouch of 2 implants 078102 PKR 5,195.31 — No comparator
Microgynon ED Fe Ethinylestradiol + Levonorgestrel 0.03 mg + 0.15 mg Tablet 3 x 28's 019520 PKR 116.48 PKR 1.39/tablet 27% below median
Mirena Levonorgestrel 52 mg Intrauterine system 1 x 1's 027351 PKR 19,528.04 PKR 19,528.04/unit No comparator
Urografin Meglumine amidotrizoate + Sodium amidotrizoate 0.66 g + 0.10 g/mL (76% w/v total) Contrast solution for injection 10 x 20ml 000080 PKR 5,135.07 PKR 25.68/mL No comparator
Urografin 76% Meglumine amidotrizoate + Sodium amidotrizoate 0.66 g/mL + 0.1 g/mL Contrast solution 1 x 100ml 000080 PKR 2,560.81 PKR 25.61/mL 36% above median
Xarelto Rivaroxaban 10 mg Tablet 1 x 5's 059057 PKR 3,315.15 PKR 663.03/tablet 20% above median
Xarelto Rivaroxaban 10 mg Tablet 1 x 14's 059057 PKR 9,285.33 PKR 663.24/tablet 20% above median
Xarelto Rivaroxaban 15 mg Tablet 1 x 7's 072549 PKR 6,112.77 PKR 873.25/tablet 24% above median
Xarelto Rivaroxaban 15 mg Tablet 1 x 14's 072549 PKR 11,614.26 PKR 829.59/tablet 18% above median
Xarelto Rivaroxaban 20 mg Tablet 1 x 7's 072550 PKR 7,736.68 PKR 1,105.24/tablet 24% above median
Xarelto Rivaroxaban 20 mg Tablet 1 x 14's 072550 PKR 14,701.01 PKR 1,050.07/tablet 18% above median
Xarelto Rivaroxaban 2.5 mg Tablet 1 x 28's 074794 PKR 6,350.41 PKR 226.80/tablet 15% above median
Xarelto Rivaroxaban 2.5 mg Tablet 1 x 14's 074794 PKR 3,341.56 PKR 238.68/tablet 21% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Bayer Pakistan Private Limited — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/bayer-pakistan-private-limited/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.